Source: https://www.justice.gov/osg/brief/hays-v-united-states-opposition
Timestamp: 2018-09-20 03:23:57
Document Index: 358271252

Matched Legal Cases: ['§ 3', 'art, 474', '§ 1365', '§ 1365', '§ 1365', '§ 843']

Hays v. United States - Opposition | OSG | Department of Justice
Hays v. United States - Opposition
No. 05-54
JON RILEY HAYS, PETITIONER
Petitioner pleaded guilty to tampering with a con sumer product, in violation of 18 U.S.C. 1365(a)(4), and obtaining a controlled substance by fraud, in violation of 21 U.S.C. 843(a)(3). The question is whether petitioner's counsel provided constitutionally ineffective assistance by failing to advise petitioner that the government could not prove the jurisdictional element of the tampering charge; failing to advise petitioner that he could assert a defense of involuntary drug addiction to the Section 843(a)(3) charge; and forcing petitioner to plead guilty by threats and misrepresentations.
The opinion of the court of appeals (Pet. App. 1a-11a) is reported at 397 F.3d 564. The memorandum and or der of the district court (Pet. App. 12a-14a) is unreported.
The judgment of the court of appeals was entered on February 10, 2005. A petition for rehearing was denied on April 6, 2005 (Pet. App. 17a-18a). The petition for a writ of certiorari was filed on July 5, 2005. The jurisdic tion of this Court is invoked under 28 U.S.C. 1254(1).
After entering a guilty plea in the United States Dis trict Court for the Southern District of Illinois, peti tioner was convicted of tampering with a consumer product, in violation of 18 U.S.C. 1365(a)(4), and obtain ing a controlled substance by fraud, in violation of 21 U.S.C. 843(a)(3). He was sentenced to 51 months of im prisonment. Petitioner did not take a direct appeal. Thereafter, petitioner filed a motion to vacate his sen tence under 28 U.S.C. 2255. The district court denied that motion, Pet. App. 15a-16a, and the court of appeals affirmed, id. at 1a-11a.
1. Petitioner was a licensed physician who practiced medicine in Illinois. After he injured his back in a car accident, petitioner took OxyContin to relieve his pain and became addicted to the drug. Although the recom mended oral dosage was 20 to 40 milligrams per day, petitioner would often inject himself daily with approxi mately 300 milligrams of the drug. Pet. App. 2a, 5a.
In order to obtain such a large quantity of Oxy- Contin, petitioner prescribed it to his patients and then stole it from them during house calls. The government argued that petitioner crushed the OxyContin, dissolved the particles in a syringe, injected patients with only a portion of the dissolved drug, and retained for his own use both the syringe filled with the drug and some of the remaining tablets. Petitioner denied that he injected patients with the dissolved OxyContin, stating that he thought "crushing something . . . would be dangerous." Pet. App. 2a. Instead, petitioner claimed that he broke pills in half or prescribed more of the drug than the pa tient needed so that he could take some of the pills for himself. Petitioner also admitted that he injected some patients with a placebo so that he could inject the entire dose of OxyContin into himself. Ibid.
2. Petitioner was charged with tampering with a con sumer product in violation of 18 U.S.C. 1365(a), which prohibits "tamper[ing] with any consumer product that affects interstate or foreign commerce" with "reckless disregard for the risk that another person will be placed in danger of death or bodily injury and under circum stances manifesting extreme indifference to such risk." He was also charged, in a separate count, with violating 21 U.S.C. 843(a)(3), which makes it a crime "knowingly and intentionally * * * to acquire or obtain possession of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge."
3. Petitioner pleaded guilty to both charges pursuant to a plea agreement. See Pet. App. 1a. Under that agreement, the government promised, in return for peti tioner's guilty plea and cooperation, not to prosecute petitioner in the Southern District of Illinois for any other offense then known to the government or to be come known to the government through petitioner's co operation (Pet. C.A. App. C at 2), to recommend a sen tence at the low end of the applicable range under the Sentencing Guidelines (id. at 6), and to recommend a three-level downward adjustment under Sentencing Guidelines § 3E1.1 for acceptance of responsibility (id. at 7).
At the subsequent change-of-plea proceeding, the district court ascertained that OxyContin is manufac tured out of state, and therefore affects interstate com merce. Pet. C.A. App. A at 32; Pet. App. 20a. The court informed petitioner that if he pleaded guilty, he would be sentenced to prison, the sentence could be at the top of the applicable sentencing range of 51-63 months of imprisonment, and neither the court nor the attorneys could control the decision whether to place him in a drug program. Id. at 8a.
The court also asked petitioner whether defense counsel, the prosecutor, or anyone else had attempted "to force" him or to "put undue pressure" on him to plead guilty. Petitioner responded, "[c]ertainly not my counsels, Judge." Pet. C.A. App. A at 22. He went on to state: "I certainly feel that the Government may attack me more vociferously on charges that probably have not much merit, but certainly I think that that is an action that they've not said so much that they would take, but that is certainly looming out there. It is a threat. I feel that this is something I had to accept, yes." Ibid.; Pet. App. 9a. In response to further inquiry by the court, petitioner stated: "[N]o, sir, nobody has quote-unquote twisted my arm to make this plea. This is done of my own free will." Pet. C.A. App. A at 24; Pet. App. 10a.
The district court accepted petitioner's plea and im posed concurrent sentences of 51 months of imprison ment for tampering with a consumer product and 48 months of imprisonment for obtaining a controlled sub stance by fraud. Pet. App. 1a.
4. Petitioner filed a pro se motion under 28 U.S.C. 2255 to vacate his sentence, alleging that his attorneys had rendered ineffective assistance in advising him to plead guilty. The district court denied that motion with out holding an evidentiary hearing. See Pet. App. 15a- 16a.
5. On appeal, petitioner argued that his guilty plea to the product tampering charge was not knowing and intelligent, and resulted from ineffective assistance of counsel, because he was unaware at the time he entered the plea that the interstate commerce element of the offense was not satisfied. Petitioner relied on the Tenth Circuit's decision in United States v. Levine, 41 F.3d 607 (1994), which held that, in order to satisfy the interstate commerce element, "the effect on interstate commerce must occur at or after the tainting." Id. at 613.
The court of appeals rejected that claim. Pet. App. 4a-7a. The court explained that because of petitioner's acts, pharmacies in Illinois were required to order OxyContin from Minnesota to replenish their sup plies-an effect on interstate commerce. Id. at 6a. The court also declined to follow Levine, and stated that a violation of Section 1365(a) occurs "whether the tamper ing takes place before, during, or after the product moves in interstate commerce." Ibid.; see id. at 5a.
The court of appeals next rejected petitioner's claim that counsel misled him about his likely sentence. Pet. App. 7a-8a. It determined that the district court had correctly informed petitioner of the consequences of his plea and that counsel's advice to petitioner was not "ob jectively unreasonable" because petitioner could have received a "substantially higher" sentence if he had gone to trial. Id. at 8a.
Finally, the court of appeals rejected petitioner's claim that his guilty plea was involuntary because the government had threatened to add charges against him if he did not plead guilty. Pet. App. 9a-11a. The court relied on petitioner's representation to the district court that his guilty plea was an act of free will and on evi dence of petitioner's guilt in the record. Id. at 10a-11a.
Petitioner contends (Pet. 11-15) that he received in effective assistance of counsel. That claim lacks merit and does not warrant review.1
1.	Petitioner argues primarily (Pet. 8-13) that his misconduct did not satisfy the interstate commerce ele ment of Section 1365(a) and that his counsel incompe tently failed to learn or advise him of that fact. To ob tain reversal of a conviction based on ineffective assis tance of counsel, a defendant must show that counsel's performance fell below an objective standard of reason ableness and that he was prejudiced as a result. Strick land v. Washington, 466 U.S. 668, 687 (1984). There is a "strong presumption" that counsel's performance "falls within the wide range of reasonable professional assistance." Id. at 689. Moreover, "in order to satisfy the 'prejudice' requirement, the defendant must show that there is a reasonable probability that, but for coun sel's errors, he would not have pleaded guilty and would have insisted on going to trial." Hill v. Lockhart, 474 U.S. 52, 59 (1985).
a.	Because petitioner's misconduct affected inter state commerce, his counsel did not act unreasonably, and certainly did not cause him any prejudice, by failing to advise him to the contrary. Congress prohibited "tamper[ing] with any consumer product that affects interstate or foreign commerce." 18 U.S.C. 1365(a). OxyContin is a consumer product that affects interstate commerce because it is shipped in interstate commerce from its place of manufacture in Minnesota to other States, in this case Illinois. See Pet. App. 5a. As the court of appeals explained, petitioner's unlawful scheme therefore required "pharmacies in Illinois * * * to or der more OxyContin from Minnesota to replenish their supplies." Id. at 6a; accord United States v. Moyer, 182 F.3d 1018, 1021 (8th Cir. 1999) (upholding Section 1365(a) conviction of physician who stole morphine from patients and replaced it with saline solution because the theft "contributed to the depletion of the hospital's mor phine supply, which in turn required the hospital to or der additional morphine" from out of state), cert. denied, 530 U.S. 1203 (2000).
b.	Petitioner argues that Section 1365(a) should be read narrowly to require that "the effects on interstate commerce [must] occur either at the time of or after the tampering, but not before." Pet. 8 (quoting United States v. Levine, 41 F.3d 607, 613 (10th Cir. 1994)). He contends (Pet. 9) that under the Tenth Circuit's decision in Levine, "the place of manufacture of the consumer product has nothing to do with a § 1365 violation."
Petitioner overreads Levine. Although the Tenth Circuit stated in that case that "the effect on interstate commerce must occur at or after the tainting" of the product, it made clear that the interstate commerce ele ment is nonetheless satisfied if: (i) "the product was in interstate commerce at the time of tainting"; (ii) the product "was returned to interstate commerce" after the tainting; or (iii) "there was an actual impact on inter state commerce as a result of the tainting." 41 F.3d at 614-615. The Tenth Circuit noted that-unlike the OxyContin at issue here-the product at issue there, a can of Diet Pepsi, "never left Colorado during its exis tence." Id. at 614 n.8. Nonetheless, the court held that the evidence was sufficient to support the conviction of a person who had purchased and then tainted a can of Diet Pepsi and reported the tainted can to the media. The court explained that the interstate commerce ele ment was satisfied because, as a result of the defen dant's misconduct, future sales of Diet Pepsi in inter state commerce would decline. Id. at 615.
There is no square conflict between Levine and the decision below. Both courts of appeals held that the in terstate commerce element was satisfied because "there was an actual impact on interstate commerce as a result of the tainting." Levine, 41 F.3d at 614-615. The Tenth Circuit explained that Levine caused Diet Pepsi sales to decline, id. at 615, while the Seventh Circuit explained that petitioner caused pharmacies in Illinois to order OxyContin from Minnesota, Pet. App. 6a. Because the Seventh Circuit's supply-and-demand analysis does not focus solely on past effects on interstate commerce, it is not in conflict with the Tenth Circuit's approach.2
Thus, although the court of appeals stated that it was declining to follow Levine and held that "a violation of § 1365(a) occurs whether the tampering takes place be fore, during, or after the product moves in interstate commerce," Pet. App. 6a, that methodological disagree ment has no significance in this case. Nor is it clear that the disagreement will be dispositive in other cases, given the fact-specific nature of the inquiry and the infre quency with which the issue arises. Indeed, Levine and the decision below are the only cases cited by petitioner on this issue, and both held that the interstate commerce element was satisfied.
c.	To the extent that there is a methodological dis agreement between the Seventh and Tenth Circuits, the decision below is correct that "a violation of § 1365(a) occurs whether the tampering takes place before, dur ing, or after the product moves in interstate commerce." Pet. App. 6a. Congress broadly prohibited "tamper[ing] with any consumer product that affects interstate or foreign commerce." 18 U.S.C. 1365(a). Congress's use of the term "affects" commerce is significant, because the phrase "affecting commerce * * * normally signals Congress' intent to exercise its Commerce Clause pow ers to the full." Allied-Bruce Terminix Cos. v. Dobson, 513 U.S. 265, 273 (1995); see Russell v. United States, 471 U.S. 858, 859 (1985); Scarborough v. United States, 431 U.S. 563, 571 (1977).
For that reason, this Court has long construed an analogous statute prohibiting felons from possessing firearms "in or affecting commerce" (18 U.S.C. 922(g)(1)) to require only "the minimal nexus that the firearm have been, at some time, in interstate com merce." Scarborough, 431 U.S. at 575 (emphasis added). Proof that a gun traveled in interstate commerce before the offense is therefore sufficient to satisfy the "affect ing commerce" element of a felon-in-possession charge. See ibid. The same analysis applies here: at a mini mum, Section 1365(a) prohibits tampering with con sumer products once they enter the stream of com merce, regardless of whether the tampering causes some additional effect on interstate commerce. Here, that means that petitioner violated the statute by tam pering with OxyContin tablets after they had traveled in interstate commerce.
d.	In light of that analysis, counsel did not render deficient performance in advising petitioner to plead guilty instead of pursuing an unmeritorious jurisdic tional defense at trial. Indeed, counsel would have been derelict in advising petitioner to go to trial based on Le vine, given that petitioner's conduct affected interstate commerce even under the analysis in that case. In any event, further review of the fact-specific questions whether the interstate commerce element is satisfied in this case, whether counsel acted unreasonably in recom mending that petitioner accept the benefits of a plea bargain instead of attempting to prevail at trial on that issue, and whether any unreasonable performance re sulted in prejudice, is not warranted.
2. Petitioner also argues (Pet. 13) that his counsel should have advised him that he could have asserted a defense of involuntary drug addiction to the charge of obtaining a controlled substance by fraud in violation of 21 U.S.C. 843(a)(3). Petitioner did not raise that conten tion in the court of appeals, and that court did not ad dress it. To the contrary, petitioner conceded in the court of appeals that he "violated 21 U.S.C. § 843(a)(3)." Pet. C.A. Reply Br. 11; accord id. at 8 n.4 ("Dr. Hays is not challenging his conviction on Count 2 except to the extent that he was sentenced to the statutory maximum on Count 2 because of the greater sentence received on Count 1."). Review should be denied for that reason alone. See, e.g., Adarand Constructors, Inc. v. Mineta, 534 U.S. 103, 109 (2001); Glover v. United States, 531 U.S. 198, 205 (2001).
Moreover, involuntary drug or alcohol addiction is not, standing alone, a valid defense. In addition to show ing that he became addicted involuntarily, petitioner would have to show that at the time of the offense he did not know the nature and quality of his acts or know that those acts were wrong. See, e.g., United States v. F.D.L., 836 F.2d 1113, 1116-1117 (8th Cir. 1988). Peti tioner could not possibly prevail on such a defense, in part because his own testimony demonstrates that he retained the capacity to make moral distinctions. For example, petitioner stated at the change-of-plea hearing that crushing OxyContin was something that he "would have never done" because it would have been "danger ous" for his patients. Pet. C.A. App. A at 35; Pet. App. 21a. At sentencing, petitioner similarly stated that he broke OxyContin tablets in half because he believed, based on consultation with a pharmacist, that doing so would not be harmful to his patients. Pet. C.A. App. B at 9-10. Counsel did not act unreasonably in failing to advise petitioner of an untenable defense, and knowl edge of such a defense could not plausibly have moti vated petitioner to plead not guilty. In any event, such a fact-bound claim does not warrant further review. See Sup. Ct. R. 10.3
3. Finally, petitioner claims (Pet. 13, 14), without elaboration, that "it is undisputed" that defense counsel used threats and misrepresentations to persuade him to plead guilty. As the court of appeals explained, the re cord does not support that claim. See Pet. App. 9a-11a. At the change-of-plea proceeding, the district judge asked petitioner whether anyone, including defense counsel, had "attempted in any way to force" him or to "put undue pressure" on him to plead guilty, and peti tioner answered, "[c]ertainly not my counsels, Judge." Pet. C.A. App. A at 22. Petitioner stated in response to further questioning from the court that "nobody has * * * twisted my arm to make this plea," and that he was pleading guilty "of my own free will." Id. at 24; Pet. App. 10a.
Nor is petitioner entitled to relief on the ground that counsel provided him with incorrect information. Peti tioner argued below that counsel erroneously told him that he would receive a prison sentence of 10-20 years if he did not plead guilty, and that a guilty plea would probably result in little or no prison time. Pet. App. 31a. Even assuming arguendo that counsel made those rep resentations, both the plea agreement (Pet. C.A. App. C at 6) and the district court at the change-of-plea pro ceeding (Pet. C.A. App. A at 15; Pet. App. 8a) correctly informed petitioner that, barring a departure, his sen tence under the Sentencing Guidelines would be 51-63 months. The district court emphasized to petitioner that he was "looking at prison time * * *, not probation" (Pet. C.A. App. A at 10), and later imposed the lowest sentence (51 months) in the range explained to peti tioner. See Pet. App. 1a.
Accordingly, at the time he pleaded guilty, petitioner had an accurate understanding of the consequences of his plea. Especially in view of the benefits of the plea (including a substantial reduction in the likely sentence, see Pet. App. 8a), and the strength of the government's case (which would have included eyewitness testimony of the patients petitioner victimized, see Pet. C.A. App. A at 31), the allegedly erroneous representations of counsel could not have affected petitioner's decision to plead guilty. In any event, petitioner's fact-bound claims do not warrant further review. See Sup. Ct. R. 10.
1	The petition does not present an issue under United States v. Booker, 125 S. Ct. 738 (2005), because, as part of the plea agreement, petitioner waived both the right to a jury trial and the right to challenge his sentence on direct appeal or collateral review. Pet. C.A. App. C at 3, 9; see Pet. App. 8a n.1 (noting that Booker "is not implicated in this case").
2	Petitioner contends (Pet. 10) that Illinois pharmacies did not need to replenish their supplies of OxyContin because his patients (to whom he prescribed the drug) "did not need it in the first place." Even assuming arguendo that the patients had no need for OxyContin or some other pain medication manufactured out of state, the net effect of petitioner's scheme was still to increase demand for OxyContin in Illinois, with the inevitable effect that more OxyContin had to be shipped from Minnesota to Illinois. See Moyer, 192 F.3d at 1021-1022 (holding that it was irrelevant whether patients' use of morphine would have resulted in same depletion of supply as doctor's theft, because "[t]he fact remains that [the doctor] stole the morphine * * * and the reduction in supply was thus a result of her actions and not theirs"). Although petitioner claims (Pet. 10) that there is no record evidence to that effect, petitioner's guilty plea relieved the government of the burden of presenting evidence at trial, and the record does reflect that OxyContin is manufactured out of state. Pet. App. 20a.
3	Although the petition for a writ of certiorari appears to raise only an ineffective-assistance-of-counsel claim, some language in the petition might be construed to raise a separate attack on the plea based upon the contention that petitioner's plea was unintelligent and involuntary because he did not understand the elements of the crime. See Pet. 14, 15. Such a claim would be procedurally defaulted because petitioner failed to raise it on direct appeal. See Bousley v. United States, 523 U.S. 614, 621 (1998). Because petitioner cannot show any cause for that failure, he would bear the burden of proving that he is actually innocent. Id. at 622. Petitioner cannot carry that burden. His sole claims of innocence (i.e., challenges to the interstate commerce element and mental state element) lack merit for the reasons explained above.
2005-0054.resp.pdf